Delivery Order SPE2DB20D3101-SPE2DB24FQUC9
- Not listed
- This federal contract award is for the delivery of TELMISARTAN 80 MG TABLET 30S, a pharmaceutical product, to the Defense Logistics Agency (DLA). The $1,183.02 Firm Fixed Price Delivery Order was awarded to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., a major pharmaceutical distributor. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that Cencora, Inc. holds with the DLA Troop Support Medical, which serves as the primary vehicle for the company to...
- This federal contract award is for the delivery of Telmisartan 80 mg tablets to the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor that serves as a key vendor for federal healthcare programs. The contract, valued at $5,522.85, is a delivery order with a firm fixed price and an ultimate completion date of November 2, 2021. There is no set-aside designation, indicating this was an open competition. Amerisourcebergen Drug Corp...
- This federal contract award is for the delivery of Telmisartan 80 mg tablets to the Defense Logistics Agency (DLA), a defense agency. The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, and has a ceiling value of $1,074.11. The contract is a Delivery Order with a Firm Fixed Price pricing type, and has an ultimate completion date of February 21, 2025. The contract is not designated as a set-aside. Amerisourcebergen Drug...
- This federal contract award is for the delivery of Telmisartan 80 mg Tablets to the Defense Logistics Agency (DLA). The contract, valued at $3,387.21, was awarded to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The award is a Delivery Order with a Firm Fixed Price, and does not have a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., for the delivery of TELMISARTAN 40 MG TABLET 30S. The contract has a ceiling value of $3,554.38 and a completion date of October 24, 2023. It is a firm fixed-price delivery order contract, with no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This federal contract award, valued at $1,371.57, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of TELMISARTAN 40 MG TABLET 30S, a pharmaceutical product, with a completion date of September 27, 2023. The contract is a Delivery Order with a Firm Fixed Price pricing type, and it was awarded on September 26, 2023. The award is not designated as a set-aside contract. Amerisourcebergen Drug Corp holds a...
- This federal contract award is for the delivery of Telmisartan 80 mg tablets to the Defense Logistics Agency (DLA), a defense agency. The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order with a Firm Fixed Price pricing type and a ceiling value of $2,208.75. The contract does not have a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is a subsidiary of the...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $3,237.60 firm fixed-price delivery order is for the supply of Telmisartan 80 mg tablets. The award has an ultimate completion date of January 31, 2024. Amerisourcebergen Drug Corp holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for the company to provide a wide range of...
- This federal contract award is for the delivery of Telmisartan 80 mg tablets to the Defense Logistics Agency (DLA), a defense agency. The contract, valued at $5,617.35, was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on May 23, 2022. The contract is a delivery order with a firm fixed price pricing type and has a completion date of May 24, 2022. This award is not designated as a set-aside contract. Amerisourcebergen Drug Corp is a subsidiary of Cencora, Inc., which...
- This federal contract award is for the delivery of Telmisartan 80 mg tablets to the Defense Logistics Agency (DLA) Troop Support Medical. The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distribution company. The contract has a firm fixed price of $1,044.00 and a completion date of June 13, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA, valued up to $999,999,999.00 through December 31, 2025. This single-award IDC serves as the...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB24FQUC9Delivery Order
This federal contract award is for the delivery of TELMISARTAN 80 MG TABLET 30S, a pharmaceutical product, to the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., a major pharmaceutical distribution company. The contract is a Delivery Order valued at $5,167.36 with a completion date of November 7, 2023. It was awarded on November 6, 2023 and has a Firm Fixed Price pricing type. There is no set-aside designation mentioned. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026. This IDC serves as the primary vehicle for the company to provide a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.2k | 11/6/23 |